Want to see GB:GENF full AI Analyst Report?
GENF Stock Chart & Stats
1.68 p
0.00 p(0.00%)
At close: 4:00 PM EDT
1.68 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range0.55 p - 3.12 p
Previous CloseN/A
Volume3.08M
Average Volume (3M)1.73M
Market Cap
£9.49M
Enterprise Value11.62M
Total Cash (Recent Filing)£111.79K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.01
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding566,409,800
10 Day Avg. Volume2,042,393
30 Day Avg. Volume1,733,703
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-14.33
Price to Sales (P/S)0.00
P/FCF Ratio-5.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Zero Financial DebtHaving zero financial debt materially reduces refinancing and interest burden risk for a cash-burning R&D company. This preserves balance-sheet flexibility to pursue partnerships, equity raises or staged development, lowering near-term insolvency risk and providing a durable buffer for ongoing programs.
Improving Cash Flow TrendAn improvement in free cash flow year-over-year suggests management is achieving better operating efficiency or cost control. For an early-stage biotech, a sustained reduction in cash burn extends R&D runway, reduces immediate financing pressure, and is a constructive, durable indicator if the trend continues.
Focused Ageing R&DA clear strategic focus on ageing biology and gene-based approaches targets a large, structurally growing market with high unmet need. Specialization in sirtuin-related and gene modalities can create technical barriers and differentiation, supporting long-term competitive advantage if programs advance clinically.
Bears Say
Pre-Revenue OperationsBeing pre-revenue with ongoing operating losses and negative cash flow means the company lacks internal funding for R&D. Over the medium term this raises execution risk, forces reliance on external capital, and lengthens the path to commercial sustainability absent successful clinical progress or partnerships.
Negative Shareholders' EquityShareholders' equity turning and staying negative reflects accumulated losses that have eroded the capital base. This structural weakness reduces the firm's ability to absorb setbacks, increases likelihood of dilutive recapitalizations, and constrains strategic optionality over multiple quarters.
Reliance On External FundingMulti-year cash burn coupled with explicit dependence on external funding creates persistent financing risk. Reliance on equity or partner capital exposes programs to market cycles and potential dilution, and can delay or curtail R&D progress if access to funds tightens over the coming months.
Genflow Biosciences Plc News
GENF FAQ
What was Genflow Biosciences Plc’s price range in the past 12 months?
Genflow Biosciences Plc lowest share price was 0.55 p and its highest was 3.12 p in the past 12 months.
What is Genflow Biosciences Plc’s market cap?
Genflow Biosciences Plc’s market cap is £9.49M.
When is Genflow Biosciences Plc’s upcoming earnings report date?
Genflow Biosciences Plc’s upcoming earnings report date is Sep 25, 2026 which is in 50 days.
How were Genflow Biosciences Plc’s earnings last quarter?
Genflow Biosciences Plc released its earnings results on Apr 30, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Genflow Biosciences Plc overvalued?
According to Wall Street analysts Genflow Biosciences Plc’s price is currently Overvalued.
Does Genflow Biosciences Plc pay dividends?
Genflow Biosciences Plc does not currently pay dividends.
What is Genflow Biosciences Plc’s EPS estimate?
Genflow Biosciences Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genflow Biosciences Plc have?
Genflow Biosciences Plc has 566,409,800 shares outstanding.
What happened to Genflow Biosciences Plc’s price movement after its last earnings report?
Genflow Biosciences Plc reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.071%.
Which hedge fund is a major shareholder of Genflow Biosciences Plc?
Currently, no hedge funds are holding shares in GB:GENF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genflow Biosciences Plc
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-1003, a topical delivery of SIRT6 to the fibroblasts in the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005, which addresses mitochondrial dysfunction observed in sarcopenia for muscle health and combat sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company has collaborative research agreements with Revatis SA and EXO Biologics for therapy medicinal products. Genflow Biosciences plc was founded in 2020 and is headquartered in London, the United Kingdom.
Technical Analysis
Oxford BioDynamics
―
Physiomics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Aptamer Group Plc
―